• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2024 May;18(5):e13284.
doi: 10.1111/irv.13284. Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom

Heather Whitaker[SUP] 1 [/SUP], Beth Findlay[SUP] 2 [/SUP], Jana Zitha[SUP] 3 [/SUP], Rosalind Goudie[SUP] 4 [/SUP], Katie Hassell[SUP] 5 [/SUP], Josie Evans[SUP] 2 [/SUP], Panoraia Kalapotharakou[SUP] 3 [/SUP], Utkarsh Agrawal[SUP] 4 [/SUP], Beatrix Kele[SUP] 6 [/SUP], Mark Hamilton[SUP] 2 [/SUP], Catherine Moore[SUP] 7 [/SUP], Rachel Byford[SUP] 4 [/SUP], Julia Stowe[SUP] 5 [/SUP], Chris Robertson[SUP] 2 8 [/SUP], Anastasia Couzens[SUP] 7 [/SUP], Gavin Jamie[SUP] 4 [/SUP], Katja Hoschler[SUP] 6 [/SUP], Kathleen Pheasant[SUP] 7 [/SUP], Elizabeth Button[SUP] 4 [/SUP], Catherine Quinot[SUP] 5 [/SUP], Tim Jones[SUP] 7 [/SUP], Sneha Anand[SUP] 4 [/SUP], Conall Watson[SUP] 5 [/SUP], Nick Andrews[SUP] 5 [/SUP], Simon de Lusignan[SUP] 4 9 [/SUP], Maria Zambon[SUP] 6 [/SUP], Christopher Williams[SUP] 10 [/SUP], Simon Cottrell[SUP] 3 [/SUP], Kimberly Marsh[SUP] 2 [/SUP], Jim McMenamin[SUP] 2 [/SUP], Jamie Lopez Bernal[SUP] 5 [/SUP]



Affiliations
Abstract

Background: We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.
Methods: A test negative design was used to estimate vaccine effectiveness.
Results: Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.
Conclusions: During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

Keywords: effectiveness; hospitalisation; influenza; vaccine.

 
Back
Top Bottom